Core C Imaging

成像核心-核心C：项目摘要/摘要 BIOCARD研究是一项纵向的观察性研究，对349名认知正常和 注册时主要为中年(平均年龄为57.1岁)。这些受试者现在已经被跟踪了长达27年。 该项目的总体目标是进一步推进临床前阿尔茨海默病的研究 通过：(1)澄清AD生物标志物(包括基于脑脊液、血液、MRI、 和PET成像)和认知；待研究的生物标记物包括几个有前途的新生物标记物 从血液、脑脊液和脑成像中提取。(2)通过与多家公司协作，最大限度地利用我们的数据 拥有可比较数据的研究小组，以及(3)提供公开可访问的数据、脑扫描和 生物标本，供该领域的研究人员使用。为了实现这些目标，我们建立了7个核心， 本申请，还包括2个项目。成像核心(核心C)负责监督 磁共振成像(MRI)扫描和正电子发射的采集和分析 在BIOCARD研究参与者中进行断层扫描(PET)。具体目标包括：(1)促进 继续获取参与者中的3T MRI扫描，(2)促进继续纵向获取 使用匹兹堡化合物B(PIB)的PET扫描，以及使用MK6240的Tau PET成像的启动，(3) 将NIH收集的1.5T体积数据与Johns收集的3T MRI体积数据整合在一起 霍普金斯，(4)将MRI和PET成像数据与临床、认知、脑脊液和血液生物标记物相结合 B和D岩芯以及项目1(5)产生的数据，以检查MRI和PET的顺序和时间 临床前阿尔茨海默病期间生物标志物的变化，(6)整合脑组织的高场MRI图像 以及(7)继续共享图像文件和 与现场调查人员提供相关的临床信息。

IMAGING CORE – CORE C: PROJECT SUMMARY/ABSTRACT The BIOCARD study is a longitudinal, observational study of 349 individuals who were cognitively normal and primarily middle aged (mean age=57.1) at enrollment. The subjects have now been followed for up to 27 years. The overall objectives of the project are to further advance the study of preclinical Alzheimer’s disease by: (1) clarifying the pattern and rate of change in AD biomarkers (including those based on CSF, blood, MRI, and PET imaging) and cognition; the biomarkers to be studied include several promising novel biomarkers derived from blood, CSF and brain imaging. (2) maximizing our data by working collaboratively with several research groups who have comparable data, and (3) providing a publicly accessible data, brain scans, and biological specimens, for researchers in the field. To accomplish these goals we established 7 Cores and, with this application, are also including 2 projects. The Imaging Core (Core C) is responsible for overseeing the acquisition and analysis of magnetic resonance imaging (MRI) scans and positron emission tomography (PET) scans in the BIOCARD study participants. The specific aims include: (1) to facilitate the continued acquisition of 3T MRI scans in the participants, (2) to facilitate the continued longitudinal acquisition of PET scans, using Pittsburgh Compound B (PiB), and the initiation of Tau PET imaging, using MK6240, (3) to integrate the 1.5T volumetric data collected at the NIH with the 3T MRI volumetric data collected at Johns Hopkins, (4) to integrate the MRI and PET imaging data with the clinical, cognitive, CSF and blood biomarker data generated by Cores B and D and Project 1, (5) to examine the order and timing of MRI and PET biomarker changes during preclinical Alzheimer’s disease, (6) to integrate high field MRI images of brain tissue with detailed neuropathological findings in the same individuals, and (7) to continue to share image files and related clinical information with investigators in the field.